Showing results (1601-1610 of 1,948) with videos related to
Sort By:
Pageof 195
The Science of the Total Environment|October 29, 2025
Pre- and post-move exposure to air pollution and neighborhood socioeconomic statusChelsea Liu, Erin E Bennett, Katie M Lynch, et al.Journal of Economic Entomology|October 9, 2021
Development of Economic Thresholds Toward Bollworm (Lepidoptera: Noctuidae), Management in Bt Cotton, and Assessment of the Benefits From Treating Bt Cotton With InsecticideWilfrid Calvin, Fei Yang, Sebe A Brown, et al.JCO Clinical Cancer Informatics|August 18, 2020
Three-Dimensional Printed Molds for Image-Guided Surgical Biopsies: An Open Source Computational PlatformMireia Crispin-Ortuzar, Marcel Gehrung, Stephan Ursprung, et al.International Journal of Particle Therapy|November 28, 2019
Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?Stephanie K Schaub, Robert D Stewart, George A Sandison, et al.Antimicrobial Agents and Chemotherapy|September 29, 2005
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitroHongmei Mo, Liangjun Lu, Tami Pilot-Matias, et al.The New Zealand Medical Journal|June 14, 1978
The Milton survey: Part 1, General methods, height, weight and 24-hour excretion of sodium, potassium, calcium, magnesium and creatinineF O Simpson, E R Nye, P Bolli, et al.Radiation and Environmental Biophysics|February 10, 2025
Analytic and Monte Carlo calculations of dose-mean lineal energy for 1 MeV-1 GeV protons with application to radiation protection quality factorAlexis Papadopoulos, Ioanna Kyriakou, Yusuke Matsuya, et al.Current Biology : CB|April 29, 2026
Symbiotic fungi underlie the regeneration potential of island rainforestsCharlie K Cornwallis, Michael E Van Nuland, Alex Wegmann, et al.Journal of Economic Entomology|February 12, 2021
Sublethal Impacts of Novaluron on Tarnished Plant Bug (Hemiptera: Miridae) AdultsBeverly D Catchot, F R Musser, J Gore, et al.Investigational New Drugs|March 4, 2005
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, H Hirte, W H Miller, et al.Pageof 195